US10450610B2ActiveUtilityA1
Single nucleotide polymorphisms (SNP) and association with resistance to immune tolerance induction
Est. expiryApr 18, 2028(~1.8 yrs left)· nominal 20-yr term from priority
A61P 37/02C12Q 2600/158C12Q 2600/106C12Q 2600/156C12Q 1/6883A61K 38/39C12Q 2600/118A61K 39/00
49
PatentIndex Score
0
Cited by
23
References
8
Claims
Abstract
This application discloses methods, systems and kits for correlating the presence or absence of certain nucleic acid sequences within a population with the ability to create immune tolerance in that same population. Tolerance can be induced by solo or repeated administration of antigen, including soluble antigens administered either intravenously or sublingually. This application also discloses methods for detecting variants. In addition the application addresses the use or avoidance of non steroidal anti inflammatory drugs in therapy.
Claims
exact text as granted — not AI-modifiedThe invention claimed is:
1. A method of diagnosing impaired oral immune tolerance in a human susceptible to a disease and treating the human by inducing oral immune tolerance, the method comprising
a. obtaining a sample from the human;
b. detecting whether SEQ ID NO: 1 is present in the sample,
c. diagnosing the human as having susceptibility to oral immune tolerance induction when SEQ ID NO: 1 is absent from the sample, and
d. inducing oral immune tolerance in the human by administering an effective amount of at least one orally administered antigen to the human.
2. The method of claim 1 , wherein detecting whether SEQ ID NO: 1 is present in the sample comprises using fluorescence in situ hybridization (FISH).
3. The method of claim 1 , wherein said disease is selected from the group consisting of asthma, Crohn's disease, Celiac disease, multiple sclerosis, idiopathic pulmonary fibrosis, and rheumatoid arthritis.
4. The method of claim 1 , wherein said disease is a sclerotic disease.
5. The method of claim 4 , wherein said sclerotic disease is systemic sclerosis.
6. The method of claim 1 , wherein said sample is selected from the group consisting of: whole blood, blood plasma, urine, tears, semen, saliva, buccal mucosa, interstitial fluid, lymph fluid, meningeal fluid, amniotic fluid glandular fluid, sputum, feces, perspiration, mucous, vaginal secretion, cerebrospinal fluid, hair, skin, fecal material, wound exudate, wound homogenate, and wound fluid.
7. The method of claim 6 , wherein said at least one orally administered antigen is a collagen.
8. The method of claim 7 , wherein said collagen is selected from the group types consisting of: I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIV, XV, XVI, XVII, XVIII, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVII, and XXVIII.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.